This company has been acquired
Cidara Therapeutics Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Cidara Therapeutics de 51.9% y 62.4% por año respectivamente. Se prevé que el BPA crezca en un 54.1% al año. Se espera que la rentabilidad financiera sea de -70.2% en 3 años.
Información clave
51.9%
Tasa de crecimiento de los beneficios
54.15%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.8% |
| Tasa de crecimiento de los ingresos | 62.4% |
| Rentabilidad financiera futura | -70.18% |
| Cobertura de analistas | Good |
| Última actualización | 28 Nov 2025 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Expanded Phase III Trial And BARDA Support Will Shape Long Term Outlook
Catalysts About Cidara Therapeutics Cidara Therapeutics develops drug Fc conjugates aimed at preventing and treating serious infectious diseases such as influenza. What are the underlying business or industry changes driving this perspective?Cidara: Merck's Acquisition Based On CD388 Flu Prevention Potential
Summary Cidara Therapeutics delivered a 1,165%+ return, driven by positive CD388 data and Merck's $221.50/share acquisition offer. CD388 achieved statistically significant prevention efficacy up to 76% in phase 2b, leading to FDA alignment for the single pivotal phase 3 ANCHOR trial. Phase 3 ANCHOR trial reached 6,000-patient enrollment; interim analysis is expected Q1 2026, with BLA submission contingent on success for this and subsequent Southern Hemisphere study start. I maintain a "Hold" rating as the Merck acquisition awaits HSR clearance, with regulatory and competitive risks remaining. Plus, no further upside as the acquisition is already announced. Read the full article on Seeking AlphaBullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
Summary Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388’s safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA’s Fast Track designation. Interestingly, CDTX reduced its workforce by 30% to concentrate on CD388. This could very well pay off if they're successful with their 2025 trials. Overall, CDTX stock trades at a reasonable valuation, so I feel it’s fair to give it a speculative “Buy” rating as a bet on CD388 in 2025. Read the full article on Seeking AlphaCidara Therapeutics: The underestimated potential of CD388
CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.Cidara spikes on $11M milestone payment from partner Mundipharma
The shares of clinical-stage biotech Cidara Therapeutics (NASDAQ:CDTX) gained over 8% pre-market Tuesday after the company announced that British drugmaker Mundipharma paid $11.1M as a milestone payment under a 2019 licensing deal. The payment follows the acceptance of the marketing authorization application (MAA) for rezafungin by the European Medicines Agency (EMA) as a treatment for fungal diseases candidemia and invasive candidiasis. While CDTX has rights for rezafungin in Japan, the company has sold the U.S. commercial rights for the drug to Melinta Therapeutics and rights for all other territories to Mundipharma. Chief Executive Jeffrey Stein said that his company remains on track to receive up to ~$108M in milestone payments as additional non-dilutive capital from partners subject to the accomplishment of events scheduled for the next two years. Read more about the CDTX’s licensing deal for rezafungin with Melinta in the U.S.Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Cidara Therapeutics (NASDAQ:CDTX) said it began dosing in a phase 2a trial of CD388 to evaluate the pre-exposure prophylactic activity of the antiviral against influenza virus. CD388 is aimed to deliver universal prevention of seasonal and pandemic influenza, the company said in A a Sept. 13 press release. Cidara said the study is being conducted under an exclusive worldwide license and collaboration with Johnson & Johnson (NYSE:JNJ), to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates (DFCs) to prevent seasonal and pandemic influenza. Multiple dose levels of CD388 will be evaluated in people who will receive a single administration of CD388 or placebo prior to influenza viral challenge. The trial is expected to enroll up to 168 healthy adults. "Because of its mode of action, CD388 has the potential to enable universal influenza coverage against all viral strains for all people, including those with compromised immune systems. We look forward to announcing the findings next year, and continuing our collaboration with Janssen who will be spearheading late-stage development," said Cidara President and CEO Jeffrey Stein.Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09. Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 383 | 3 | -35 | N/A | 4 |
| 12/31/2027 | 12 | -217 | -147 | -138 | 6 |
| 12/31/2026 | 10 | -172 | -131 | -311 | 6 |
| 12/31/2025 | N/A | -179 | -151 | -118 | 5 |
| 9/30/2025 | N/A | -185 | -133 | -133 | N/A |
| 6/30/2025 | N/A | -117 | -129 | -129 | N/A |
| 3/31/2025 | 0 | -186 | -192 | -192 | N/A |
| 12/31/2024 | 1 | -170 | -177 | -177 | N/A |
| 9/30/2024 | 4 | -126 | -160 | -160 | N/A |
| 6/30/2024 | 13 | -114 | -125 | -125 | N/A |
| 3/31/2024 | 18 | -26 | -19 | -18 | N/A |
| 12/31/2023 | 23 | -25 | -23 | -22 | N/A |
| 9/30/2023 | 31 | -34 | -31 | -31 | N/A |
| 6/30/2023 | 62 | -18 | -1 | -1 | N/A |
| 3/31/2023 | 64 | -22 | -16 | -16 | N/A |
| 12/31/2022 | 23 | -22 | -29 | -28 | N/A |
| 9/30/2022 | 61 | -33 | -22 | -22 | N/A |
| 6/30/2022 | 28 | -63 | -62 | -62 | N/A |
| 3/31/2022 | 54 | -44 | -47 | -47 | N/A |
| 12/31/2021 | 50 | -42 | -25 | -25 | N/A |
| 9/30/2021 | 46 | -47 | -21 | -21 | N/A |
| 6/30/2021 | 41 | -47 | -24 | -24 | N/A |
| 3/31/2021 | 12 | -74 | -41 | -41 | N/A |
| 12/31/2020 | 12 | -75 | -55 | -54 | N/A |
| 9/30/2020 | 10 | -67 | -59 | -58 | N/A |
| 6/30/2020 | 27 | -47 | -28 | -28 | N/A |
| 3/31/2020 | 23 | -42 | -27 | -27 | N/A |
| 12/31/2019 | 21 | -41 | -29 | -29 | N/A |
| 9/30/2019 | 19 | -39 | -27 | -27 | N/A |
| 6/30/2019 | N/A | -56 | N/A | -56 | N/A |
| 3/31/2019 | N/A | -69 | N/A | -59 | N/A |
| 12/31/2018 | N/A | -69 | N/A | -57 | N/A |
| 9/30/2018 | N/A | -70 | N/A | -53 | N/A |
| 6/30/2018 | N/A | -69 | N/A | -54 | N/A |
| 3/31/2018 | N/A | -59 | N/A | -50 | N/A |
| 12/31/2017 | N/A | -56 | N/A | -50 | N/A |
| 9/30/2017 | N/A | -57 | N/A | -52 | N/A |
| 6/30/2017 | N/A | -57 | N/A | -46 | N/A |
| 3/31/2017 | N/A | -52 | N/A | -43 | N/A |
| 12/31/2016 | N/A | -48 | N/A | -40 | N/A |
| 9/30/2016 | N/A | -44 | N/A | -35 | N/A |
| 6/30/2016 | N/A | -41 | N/A | -34 | N/A |
| 3/31/2016 | N/A | -35 | N/A | -31 | N/A |
| 12/31/2015 | N/A | -32 | N/A | -26 | N/A |
| 9/30/2015 | N/A | -27 | N/A | -22 | N/A |
| 6/30/2015 | N/A | -21 | N/A | -18 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que CDTX siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que CDTX siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que CDTX siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (62.4% al año) de CDTX crezcan más rápidamente que los del mercado US (11.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (62.4% al año) de CDTX crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: CDTX se prevé que no sea rentable en 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/01/06 11:12 |
| Precio de las acciones al final del día | 2026/01/06 00:00 |
| Beneficios | 2025/09/30 |
| Ingresos anuales | 2024/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cidara Therapeutics, Inc. está cubierta por 8 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Timothy Chiang | BTIG |
| Eun Kyung Yang | Jefferies LLC |
| Kevin DeGeeter | Ladenburg Thalmann & Company |